Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00946881 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer
A Phase 1 study of Prostate Cancer, sponsored by Steba Biotech S.A..
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 5
- Study locations
NCT00946881 is a Phase 1 study of Prostate Cancer that has completed, run by Steba Biotech S.A.. The registered enrollment target is 30 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT00946881, a Phase 1 study of Prostate Cancer, has completed, sponsored by Steba Biotech S.A..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 5
- Study locations
Study Summary
The aim of this study is to determine the optimal treatment conditions (WST11 dose and light energy dose) to achieve ablation in one lobe of the prostate and to evaluate the safety and quality of life of WST11 medicated Vascular-Targeted Photodynamic therapy (VTP) in men with localized prostate cancer.
Conditions Studied
Interventions
- DRUG WST 11 -mediated -VTP
Study Locations (5)
New York
- NYU Urology Associates - New York
- Memorial Sloan-Kettering Cancer Center - New York
California
- UCLA - Jonsson Comprehensive Cancer Center - Los Angeles
Georgia
- Midtown Urology & Midtown Urology Surgical Center - Atlanta
Missouri
- Washington University School of Medicine- Barnes-Jewish Hospital - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2009-07 |
| Est. Completion | 2012-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00946881
The ClinicalTrials.gov registry entry for NCT00946881 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Steba Biotech S.A., which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which WST 11 -mediated -VTP is the first listed.
NCT00946881 reports 5 study locations spanning 4 distinct geographic areas - top geographies include New York, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT00946881 about?
NCT00946881 is a clinical study titled "Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer". The aim of this study is to determine the optimal treatment conditions (WST11 dose and light energy dose) to achieve ablation in one lobe of the prostate and to evaluate the safety and quality of life of WST11 medicated Vascular-Targeted Photodynamic therapy (VTP) in men with localized prostate canc...
What is the current status of trial NCT00946881?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2009-07. Estimated completion is 2012-08.
What conditions does trial NCT00946881 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00946881?
The interventions under investigation include: WST 11 -mediated -VTP (DRUG).
Who is sponsoring clinical trial NCT00946881?
This trial is sponsored by Steba Biotech S.A., which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00946881 being conducted?
This trial has 5 study locations across California, Georgia, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.